We are at the forefront of innovation, adapting to shifting societal needs and turning scientific and technological advancements into transformational solutions for patients. In everything we do, we strive to make a positive impact on patients, society and the environment – now, and for generations to come.
“Prevention and access to diagnostics and innovative therapies are an investment in the future – reducing the long-term burden on healthcare systems.”
Dr Severin Schwan
Chairman
“2024 was a year of great progress for Roche, with a new strategy, important innovations for patients and strong financial results.”
Dr Thomas Schinecker
CEO Roche Group
We are creating a healthier future, together.
Keeping patients at the heart of everything we do, our ambition is clear: to prevent, stop, and cure diseases, and, with that, improve outcomes and reduce costs for patients and healthcare systems worldwide.
For over 125 years, Roche has taken on some of the most complex challenges in healthcare. So we all have more time with the people we love. Today, patient needs are changing faster than ever. And as society, technology, politics and science evolve with incredible speed, so must healthcare. We need to find solutions that meet patients where they are today and in the future. To rise to this challenge, we must harness our combined strengths in diagnostics and pharmaceuticals to prevent, stop, and cure the diseases that have the greatest impact on society. At Roche, we turn challenges into opportunities, always innovating. It's time to act. It's time to make a bigger impact by tackling the toughest diseases. It's time to build a healthier future together.
Discover how Roche made an impact in 2024
Roche is uniquely positioned to lead the way for better healthcare with its Diagnostics and Pharmaceuticals under one roof.
We're creating a healthier future now and for generations to come. In 2024, we advanced healthcare.
With bold strategies, innovative diagnostics and medicines, and strong financial results, we laid the foundation for a sustainable future — for science, patients, society and our company. We have a clear path ahead: to prevent, stop and cure diseases. Putting patients first, we strive to improve outcomes while lowering costs for patients and healthcare systems worldwide. From hospitals to homes, we're meeting patients where they need us — improving access and improving lives. With diagnostics and pharmaceuticals under one roof, Roche is uniquely positioned to lead the way for better healthcare. But innovation doesn't happen in isolation: Our new Roche Innovation Center in Basel, – a state-of-the-art lab and workspace, – enables collaboration and creativity to accelerate breakthroughs. And through key partnerships and acquisitions in ophthalmology, cancer, cell therapy and diagnostics, we’re driving transformative progress for patients. We have a deep commitment to our people, culture and values. In everything we do, we create a healthier future together – now, and for generations to come.
Performance figures 2024
Group sales:
CHF 60.495 million
Pharmaceuticals sales:
CHF 46.171 million
Diagnostics sales:
CHF 14.324 million
Core operating profit:
CHF 20.823 million
R&D core investments:
CHF 13.042 million
Dividend proposal:
CHF 9.70
*Unless otherwise stated, all growth rates and year-on-year comparisons are at constant exchange rates (CER; 2023 average) and all total figures are reported in Swiss francs.
Key Highlights 2024
Roche extended its partnership with City Cancer Challenge, committing to a new three-year partnership in a collaboration that reaches an estimated 66.5 million people.
in scope of our low- and lower-middle-income country (LLMIC) access goal used our core medicines in 2024, as we aim to double access from 27,000 patients in 2021 until 2026.
were treated with Roche medicines in 2024, compared to 37 countries in 2023 and 33 countries in 2021.
were approved or future approval was in progress in LLMICs in 2024, compared to 68% in 2023 and 60% in 2021.
delivered to our customers worldwide in 2024.
were screened for risk of cervical cancer using Roche’s HPV tests – around 740,000 in markets served by the Global Access Program, compared to 300,000 in 2023.
*Low-lower-middle-income countries (LLMICs)
Xolair
Alecensa
PiaSky
Tecentriq Hybreza (SC)
Ocrevus SC
Itovebi + palbociclib + fulvestrant
Tecentriq SC
Alecensa
Ocrevus SC
Vabysmo
PiaSky
PiaSky
Vabysmo
Alecensa
PiaSky
Vabysmo
CellCept
Alecensa
Evrysdi
Lunsumio
1 new platform
2 new tests
6 new tests
3 new platforms
10 new tests
1 new platform
3 new tests
2 new digital solutions
5 new digital solutions
Committed to the path ahead
The Head Corporate Strategy and Sustainability and Roche’s Chief Sustainability Officer, discussing the critical role of sustainability for future success – for Roche and society.